Insurers won't cover new Alzheimer's treatment for some cust

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.

Related Keywords

Japan , New York , United States , Cambridge , Cambridgeshire , United Kingdom , Boston , Massachusetts , West Virginia , Cheektowaga , Delaware , Tufts Medical Center , North Carolina , Pennsylvania , Japanese , Juliette Cubanski , Christine Mann , James Chambers , Kaiser Permanente , Greg Warren , Bonnie Bortz , Jack Hoadley , Heidi Syropoulos , Society Of Actuaries , Drug Administration , Howard Hughes Medical Institute Science , Associated Press , Biogen Inc , Science Department , Elevance Health , Georgetown University Center On Health Insurance Reforms , Educational Media Group , N Dent Neurologic Institute , Massachusetts Based Biogen , Dent Neurologic Institute , Blue Cross , Blue Shield , Philadelphia Based Independence Blue , Blue Cross Shield , Medicare Advantage , Medical Center , Georgetown University , Health Insurance , Associated Press Health , Howard Hughes Medical Institute , Educational Media , Yap , Alzheimer X27s , Insurers , Treatment ,